Chipscreen(SH:688321) Mei Ri Jing Ji Xin Wen·2025-11-26 16:32Core Viewpoint - The major shareholder of Microchip Biotech, Boao Biological Group, has completed a share reduction plan, selling 12.23 million shares, which is 3% of the company's total equity, for approximately 322 million yuan. This reduction will not significantly impact the company's governance structure or operations [2][7][8]. Group 1: Shareholder Actions - Boao Biological Group, the largest shareholder of Microchip Biotech, held 34.71 million shares (8.51% of total equity) before the reduction [7]. - The share reduction was initiated on September 11, 2025, due to strategic funding needs, with a plan to sell up to 12.23 million shares through a combination of centralized bidding and block trading [7][8]. - The reduction was executed between October 14 and November 26, 2025, with a total of 407.80 million shares sold through centralized bidding and 815.59 million shares through block trading, at prices ranging from 23.59 yuan to 31.10 yuan per share [8]. Group 2: Company Financing Plans - Microchip Biotech is advancing a plan to issue A-shares to specific investors, aiming to raise up to 950 million yuan for innovative drug research, the construction of a new drug manufacturing base, and to supplement working capital [9]. - The fundraising plan has been approved by the company's board and shareholders, pending approval from the Shanghai Stock Exchange and registration with the China Securities Regulatory Commission [9]. - The funds will be allocated as follows: 350 million yuan for innovative drug research, 350 million yuan for the first phase of the new drug manufacturing base, and 250 million yuan for working capital [11]. Group 3: Research and Development Focus - Microchip Biotech is focusing on multiple key Phase II and III clinical trials, including a Phase II study for a combination treatment for advanced pancreatic ductal adenocarcinoma and a Phase III study for a colorectal cancer indication [11][12]. - The company reported significant revenue growth for its products, with a 125.7% year-on-year increase for one drug in the first half of 2025 and an 18.8% increase for another in the same period [11][12].